- Home
- CHYM vs EXAS Comparison
CHYM vs EXAS Comparison
Compare CHYM & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHYM
- EXAS
- Stock Information
- Founded
- CHYM 2012
- EXAS 1995
- Country
- CHYM United States
- EXAS United States
- Employees
- CHYM N/A
- EXAS N/A
- Industry
- CHYM Finance: Consumer Services
- EXAS Medical Specialities
- Sector
- CHYM Finance
- EXAS Health Care
- Exchange
- CHYM Nasdaq
- EXAS Nasdaq
- Market Cap
- CHYM 10.8B
- EXAS 10.7B
- IPO Year
- CHYM 2025
- EXAS N/A
- Fundamental
- Price
- CHYM $30.09
- EXAS $51.91
- Analyst Decision
- CHYM Buy
- EXAS Strong Buy
- Analyst Count
- CHYM 12
- EXAS 20
- Target Price
- CHYM $38.00
- EXAS $70.26
- AVG Volume (30 Days)
- CHYM 5.9M
- EXAS 2.8M
- Earning Date
- CHYM 08-07-2025
- EXAS 07-30-2025
- Dividend Yield
- CHYM N/A
- EXAS N/A
- EPS Growth
- CHYM N/A
- EXAS N/A
- EPS
- CHYM N/A
- EXAS N/A
- Revenue
- CHYM $1,800,041,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- CHYM N/A
- EXAS $14.58
- Revenue Next Year
- CHYM N/A
- EXAS $12.75
- P/E Ratio
- CHYM N/A
- EXAS N/A
- Revenue Growth
- CHYM 30.88
- EXAS 11.57
- 52 Week Low
- CHYM $28.21
- EXAS $39.97
- 52 Week High
- CHYM $44.94
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- CHYM N/A
- EXAS 44.34
- Support Level
- CHYM N/A
- EXAS $52.00
- Resistance Level
- CHYM N/A
- EXAS $55.90
- Average True Range (ATR)
- CHYM 0.00
- EXAS 2.31
- MACD
- CHYM 0.00
- EXAS -0.04
- Stochastic Oscillator
- CHYM 0.00
- EXAS 24.90
About CHYM Chime Financial Inc. Class A Common Stock
Chime Financial Inc is a financial technology company that believes in core banking services.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.